Streptozocin 1g powder for solution for infusion vials
Requires a prescription from a doctor or prescriber
An antibiotic that is produced by Stretomyces achromogenes.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Streptozocin
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Streptozocin
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
2 branded products available
MHRA licensed products
View all licensed products for Streptozocin on the MHRA register
Zanosar 1g powder for concentrate for solution for infusion vials
Therapeutically similar medicines
Tablets & capsules
(3)Injectables
(1)Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 28 studies.
1980–2026
Showing all 28 studies, sorted by most relevant.
Chao Zhang, Jianjun Deng, Dan Liu, et al.
British Journal of Pharmacology, 2018
- Aporphines
- Diabetes Mellitus, Experimental
- Fatty Liver
Charles G. Moertel, Myrto Lefkopoulo, Stuart Lipsitz, et al.
New England Journal of Medicine, 1992
- Antineoplastic Agents
- Antineoplastic Combined Chemotherapy Protocols
- Doxorubicin
Charles G. Moertel, James A. Hanley, Lewis A. Johnson
New England Journal of Medicine, 1980
- Clinical Trials as Topic
- Fluorouracil
- Adenoma, Islet Cell
Yao Liu, Jianjun Deng, Daidi Fan
Food & function, 2019
- Blood Glucose
- Diabetes Mellitus, Type 2
- Gluconeogenesis
Benhong Zhou, Qiaoling Li, Jing Wang, et al.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2019
- Creatinine
- Diabetic Nephropathies
- Ellagic Acid
Min-You Qi, Yinghao He, Yin Cheng, et al.
Food & function, 2021
- Diabetes Mellitus, Experimental
- Diabetic Nephropathies
- Flavonoids
Jiahao Wang, Guangqin An, Xi Peng, et al.
International journal of biological macromolecules, 2024
- Gastrointestinal Microbiome
- Diabetes Mellitus, Type 2
- Feces
Jianjun Deng, Yao Liu, Zhiguang Duan, et al.
Frontiers in Pharmacology, 2017
Ginsenoside is a major active component of ginseng, which exhibits various pharmacological properties such as hepatoprotection, tumor suppression and diabetes resistance. In this study, the anti-diabetic effects of protopanaxadiol (PPD) and protopanaxatriol (PPT)-type saponins were explored and compared in high-fat diet/streptozocin-induced type 2 diabetes mellitus (T2DM) mice. Our results showed that low or high dose (50 mg/kg bodyweight or 150 mg/kg bodyweight) PPD and PPT significantly reduced fasting blood glucose, improved glucose tolerance and insulin resistance in T2DM mice. PPD and PPT also regulated serum lipid-related markers such as reduced total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol in T2DM mice. In addition, PPD and PPT dramatically ameliorated the inflammatory responses by suppressing the secretion of pro-inflammatory cytokines like tumor necrosis factor-alpha and interleukin-6 in serum level and gene expression in liver level, and improved the antioxidant capacity by increasing the superoxide dismutase and decreasing malondialdehyde levels in the serum of T2DM mice. Moreover, the anti-diabetic effect of PPD and PPT appeared to be partially mediated by the suppression of hepatic metabolism genes expression such as peroxisome proliferator-activated receptor gamma coactivator 1-alpha, phosphoenolpyruvate carboxykinase, and glucose-6-phosphatase, as well as facilitating lipid metabolism genes expression such as microsomal TG transfer protein in the liver tissues of T2DM mice. Taken together, our results indicated that PPD and PPT might potentially act as natural anti-diabetic compounds to be used for preventing and treating the T2DM and its complications in the future.
Abstract licence: CC BY
V. Pilipenko, Karīna Narbute, J. Pupure, et al.
European journal of pharmacology, 2020
- Morris Water Maze Test
- Acetylcholinesterase
- Alzheimer Disease
Yixian Zhang, Yang-wei Wang, Manyu Luo, et al.
Peptides, 2019
- Diabetes Mellitus, Experimental
- Diabetes Mellitus, Type 1
- Diabetic Nephropathies
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
5-15 minutes
Mechanism
Although its mechanism of action is not completely clear, streptozocin is known…
Food interactions
None known
Human targets
3 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
17-25%
Half-life
5-15 minutes
Metabolism
Elimination
20%
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 534 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins and enzymes this drug interacts with in the body
PMID:16186102 PMID:23396969 PMID:28083649 PMID:8027028 PMID:8457197
Likely mediates the bidirectional transfer of glucose across the plasma membrane of hepatocytes and is responsible for uptake of glucose by the beta cells; may comprise part of the glucose-sensing mechanism of the beta cell .
PMID:8027028
May also participate with the Na(+)/glucose cotransporter in the transcellular transport of glucose in the small intestine and kidney .
PMID:3399500
Also able to mediate the transport of dehydroascorbate PMID:23396969
PMID:11148210 PMID:11788610 PMID:20673219 PMID:22365600 PMID:24088714 PMID:28939839 PMID:37962578
Deglycosylates a large and diverse number of proteins, such as CRYAB, ELK1, GSDMD, LMNB1 and TAB1 .
PMID:28939839 PMID:37962578
Can use p-nitrophenyl-beta-GlcNAc and 4-methylumbelliferone-GlcNAc as substrates but not p-nitrophenyl-beta-GalNAc or p-nitrophenyl-alpha-GlcNAc (in vitro) .
PMID:20673219
Does not bind acetyl-CoA and does not have histone acetyltransferase activity PMID:24088714
Enzymes involved in drug metabolism — important for understanding drug interactions
Proteins that transport this drug across cell membranes
PMID:2897240 PMID:35970996 PMID:8898203 PMID:9038218 PMID:35507548
Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins .
PMID:8898203
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells PMID:2897240 PMID:35970996 PMID:9038218
ATC L01AD04
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Streptozocin
Additional database identifiers
Drugs Product Database (DPD)
8564
ChemSpider
27273
ZINC
ZINC000003875017
GenBank Gene Database
AE015928
GenBank Protein Database
29337303
UniProt Accession
OGA_BACTN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:11006
GenAtlas
SLC2A2
GeneCards
SLC2A2
GenBank Gene Database
J03810
GenBank Protein Database
307125
UniProt Accession
GTR2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:7056
GeneCards
OGA
Guide to Pharmacology
3101
UniProt Accession
OGA_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2595
GeneCards
CYP1A1
GenBank Gene Database
K03191
GenBank Protein Database
181276
Guide to Pharmacology
1318
UniProt Accession
CP1A1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2596
GenAtlas
CYP1A2
GeneCards
CYP1A2
GenBank Gene Database
Z00036
Guide to Pharmacology
1319
UniProt Accession
CP1A2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2631
GeneCards
CYP2E1
GenBank Gene Database
J02625
GenBank Protein Database
181360
Guide to Pharmacology
1330
UniProt Accession
CP2E1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:40
GenAtlas
ABCB1
GeneCards
ABCB1
GenBank Gene Database
M14758
GenBank Protein Database
307180
Guide to Pharmacology
768
UniProt Accession
MDR1_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q257331), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.